针对心肌细胞的酸可提供阿米奥达龙
Maliha Zahid1, Beth Weber2, Ray Yurko3
1Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA.
Pharmaceutics
|August 26, 2023
概括
使用心肌细胞向性 (CTP) 向性输送阿米奥达龙显著降低了所需剂量,同时保持有效性. CTP-阿米奥达龙结合剂有效地减缓了几内亚猪心脏的导电速度和减少了作用潜力的持续时间.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物医学工程 生物医学工程
背景情况:
- 阿米奥达龙是一种抗心律失常药物,受到显著的非目标毒性限制.
- 需要有针对性的输送策略来改善amiodarone的治疗指数.
研究的目的:
- 开发和评估一种使用心肌细胞向性 (CTP) 的新型阿米奥达龙合物.
- 在几内亚猪模型中评估CTP-amiodarone的疗效和心脏电生理学影响.
主要方法:
- 合成CTP并与阿米奥达龙结合.
- 评估了结合物的稳定性.
- 几内亚猪接受了载体,阿米奥达龙,CTP-阿米奥达龙或CTP.
- 测量了心脏电生理学 (导电速度,作用电位持续时间,Ca2+短暂持续时间).
- 在心脏组织上进行了RNA测序.
主要成果:
- 在37°C下,CTP-阿米奥达龙结合剂的稳定性达到了21天.
- 大约1/15剂的CTP-阿米奥达龙显著减缓了心脏导电速度,与单独的阿米奥达龙相比.
- CTP-阿米奥达龙和CTP显著降低了动作潜力的持续时间和Ca2+过渡持续时间.
- 仅CTP就增加了Ca处理基因 (DHPR,SERCA2a) 的表达,并减少了促炎基因.
结论:
- 在显著较低的剂量下,CTP促进了阿米奥达向心肌细胞的输送.
- 通过CTP调节的动作潜力和Ca2+短暂持续时间的减少可能涉及对Ca-处理基因的调节.
- 这种有针对性的方法有望降低阿米奥达龙的毒性,同时保持其抗心律失常作用.
相关概念视频
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiopulmonary Resuscitation IV: Pharmacological Management
19
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
19
Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Heart Failure Drugs: Inotropic Agents
618
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
618
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K


